Regions Financial Corporation Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Regions Financial Corporation Common Stock trades at $26.93 (market cap $23.01B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Regions Financial Corporation Common Stock is far larger — about 12.8× Vir Biotechnology Inc. Common Stock's market cap, and Regions Financial Corporation Common Stock pays a 4.05% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regions Financial Corporation Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| RF | VIR | |
|---|---|---|
Market Cap | $23.01B | $1.80B |
Volume | 10,095,088 | 1,782,836 |
Sector | Financials | Health |
52-Week High | $32.40 | $11.78 |
52-Week Low | $23.35 | $5.12 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.75B | $1.36B |
Dividend Yield | 4.05% | — |
Signals from Pluang's Aura AI — not financial advice
Regions Financial (RF) trades at $27.01, down 1.32% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.98, net income margin of 29.3%, and consistent earnings beats in recent quarters. Recent news highlights dividend declarations and upcoming Q3 earnings, while the company plans significant branch expansion.
The outlook is cautiously optimistic with a $32.78 consensus price target suggesting 21% upside. Key risks include elevated expenses and weaker capital markets revenue. Analyst sentiment is mixed with 40% buy ratings, but institutional interest remains strong with Bank of America's recent $219 million investment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Regions Financial is a financial holding company that operates through Regions Bank. It provides consumer, commercial, mortgage, wealth-management, and investment services across the South, Midwest, and Texas.
Read more on RF →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →